Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Case

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|September 7, 2005
Quantifying the indirect treatment effect via surrogate markersYongming Qu, Michael Case
Biometrics|September 11, 2007
Quantifying the effect of the surrogate marker by information gainYongming Qu, Michael Case
The Journal of Clinical Psychiatry|June 16, 2011
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label studyVicki Poole Hoffmann, Michael Case, Jennie G Jacobson
BMC Psychiatry|September 16, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapineMichael Case, Tamas Treuer, Jamie Karagianis, et al.
Clinical Pharmacology in Drug Development|January 18, 2020
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of PropranololMax Tsai, Michael Case, Paul Ardayfio, et al.
Journal of Clinical Psychopharmacology|July 16, 2010
Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective studyStephen Z Levine, Jonathan Rabinowitz, Michael Case, et al.
Journal of Clinical Psychopharmacology|April 22, 2011
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depressionElisabeth K Degenhardt, Hassan H Jamal, Susan Tormey, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 9, 2022
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimatesAlette M Wessels, Dorene M Rentz, Michael Case, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trialsVicki P Hoffmann, Michael Case, Virginia L Stauffer, et al.
Depression and Anxiety|May 20, 2006
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depressionSara A Corya, Doug Williamson, Todd M Sanger, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|September 7, 2005
Quantifying the indirect treatment effect via surrogate markersYongming Qu, Michael Case
Biometrics|September 11, 2007
Quantifying the effect of the surrogate marker by information gainYongming Qu, Michael Case
The Journal of Clinical Psychiatry|June 16, 2011
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label studyVicki Poole Hoffmann, Michael Case, Jennie G Jacobson
BMC Psychiatry|September 16, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapineMichael Case, Tamas Treuer, Jamie Karagianis, et al.
Clinical Pharmacology in Drug Development|January 18, 2020
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of PropranololMax Tsai, Michael Case, Paul Ardayfio, et al.
Journal of Clinical Psychopharmacology|July 16, 2010
Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective studyStephen Z Levine, Jonathan Rabinowitz, Michael Case, et al.
Journal of Clinical Psychopharmacology|April 22, 2011
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depressionElisabeth K Degenhardt, Hassan H Jamal, Susan Tormey, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 9, 2022
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimatesAlette M Wessels, Dorene M Rentz, Michael Case, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trialsVicki P Hoffmann, Michael Case, Virginia L Stauffer, et al.
Depression and Anxiety|May 20, 2006
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depressionSara A Corya, Doug Williamson, Todd M Sanger, et al.
Pageof 4